Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients
Abstract Circulating tumor DNA (ctDNA) sensitivity remains subpar for molecular residual disease (MRD) detection in bladder cancer patients. To remedy this problem, we focused on the biofluid most proximal to the disease, urine, and analyzed urine tumor DNA in 74 localized bladder cancer patients. W...
Main Authors: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-01-01
|
Series: | npj Precision Oncology |
Online Access: | https://doi.org/10.1038/s41698-022-00345-w |